Made
possible by charitable contributions from Medivation Astellas
Genentech ,
Millennium
Accuray Cyberknife.
Click to Zoom
Our monthly newsletter, the HotSheet, highlights the latest in treatment strategies as well as emerging treatments. The HotSheet is distributed
free at chapter support group meetings, and is available in PDF on the Us TOO web site.
HotSheet Personal Subscriptions Now Available
If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office.
Download and print a subscription order form
or order online .
January - March |
April - June | July - September October - December
January View Newsletter
February View Newsletter
March View Newsletter
FDA Expands Zytiga’s Use for Late-Stage CRPC Prior to Chemotherapy
Adding Testosterone to Sildenafil Does Not Benefit Men with Erectile Dysfunction
Aerobic Exercise Eases Fatigue in Patients with Breast and Prostate Cancer
Diagnostic Performance of PCA3 for Detecting Prostate Cancer in Men with an Elevated PSA
Phase II Study of Cabozantinib in Men with Advanced Prostate Cancer
Doc Moyad’s “No Bogus Science” Column – “What Has 150 Calories & Stifles Weight
Ask Doctor Snuffy Myers
Doctor Chodak’s Bottom Line
Index of Articles Published in 2012 HotSheets
Protons for Prostate Cancer: Fleeting Quality of-Life Benefits
Updated Partin Tables Now Available
Radium-223 New Drug Application Submitted
Cost of Prostate Cancer Treatments Compared
Do Genetic Markers Improve Prostate Cancer Risk Prediction After an Initial Negative Biopsy?
Targeted Prostate Biopsy May Improve Care
2-Weekly Vs. 3-Weekly Docetaxel
Association of Adiponectin & Leptin with Stage & Grade of PSA-Detected Prostate Cancer
Be Prepared, by Ray Marsh, Us TOO, UK
Antioxidants – the Enemy in Cancer
Treatment?
Ask Doctor Snuffy Myers
Doc Moyad’s “No Bogus Science” Column
– “Is It Time to Discuss Metformin with Your
MD?”
Doctor Chodak’s Bottom Line
Similar Function after Surgery & Radiation
‘Smarter’ PSA Testing Strategies Proposed
REDUCE Study & Rates of Prostate Cancer
10-Year Oncologic Outcomes after Low Dose Rate Brachytherapy for Prostate Cancer
Low Neutrophil Count & Prostate Biopsies
Regaining Continence After Prostate Surgery
Identification Errors in Prostate Biopsies
Prostatectomy Outcomes in Low-Risk Cancer
T2–Diffusion-Weighted MRI & Adverse Post-prostatectomy Pathologic Outcome
High Fiber Diet & Prostate Cancer Progression
Ask Doctor Snuffy Myers
Doc Moyad’s “No Bogus Science” Column – “Exercise & Statins & Prostate Cancer Death”
April View Newsletter
May View Newsletter
June View Newsletter
Shorter ADT Duration Ok in High-Risk Cancer
Prostate Cancer Overtreatment Costs $32M
Updated Survival Benefits with Abiraterone
Prostate Health Index vs. PCA-3 Urine Test
25-Year Survival Rate After Irradiation
Identifying Prostate Cancer by Changes in PSA
Male-Pattern Baldness & Prostate Cancer Risk
Doc Moyad’s “No Bogus Science” Column – “More About Mediterranean Diets”
Ask Doctor Snuffy Myers
Clues Found to Prostate Cancer Upgrading
Long-Term RT Outcomes in Men Under 60
Dasatinib Fails in Phase III CRPC Trial
Doctor Chodak’s Bottom Line
Intermittent Hormone Treatment for Prostate Cancer Not the Best
Additional Role for Abiraterone in CRPC
Degarelix Showing Promise in Prostate Cancer
Long-Term PSA Velocity in Improved Classifi-cation of Prostate Cancer Risk & Mortality
Benign Glandular Tissue at Radica
Prostatectomy Surgical Margins
Doc Moyad’s “No Bogus Science” Column – “End of the Line for High-Dose Selenium”
Richard Petty Teams Up With Janssen Biotech to Launch “Show Your Stripes for Prostate Cancer Awareness”
Congressionally Directed Medical Research Programs Research Funding for 2013
Doctor Chodak’s Bottom Line
AUA & ASTRO Issue Joint Guideline for Postsurgery Radiotherapy
New AUA Guideline for Castrate-Resistant Prostate Cancer
AUA Issues New Guidelines on PSA Screening
Cancer Immunotherapy: An Overview
Doc Moyad’s “No Bogus Science” Column – “Former Smokers – Beware of Beta-carotene”
High-Dose Radiotherapy: Better Local Con-trol, Not Survival
Gene Test For Prostate Cancer Shows Promise
Midlife PSA Test Predicts Future Prostate Cancer Risk
Doctor Chodak’s Bottom Line
July View Newsletter
August View Newsletter
September View Newsletter
Xofigo (Radium-223) Approved for Prostate Cancer with Bone Metastases
Prostate Cancer with Faulty BRCA2 Gene Spreads More Quickly
How Likely Is Prostate Cancer To Kill?
Itraconazole vs. Advanced Prostate Cancer
Can A Gene Test Predict Prostate Cancer?
Doc Moyad’s “No Bogus Science” Column – “Vitamin C Can Cause Kidney Stones”
New AUA Guidelines on PSA Screening
Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
June is Men’s Health Month
Enzalutamide in Advanced, Hormone Naïve Prostate Cancer Reduces PSA
Doctor Chodak’s Bottom Line
Active Surveillance May Miss Aggressive Prostate Cancers in Black Men
Advanced Treatment Technologies for Men with Low Risk Prostate Cancer
Observation – Better Efficacy, Cost, QoL
Cross-resistance with Novel Androgen Blockers in Prostate Cancer
Doc Moyad’s “No Bogus Science” Column –
Fish Oil Flops in 2012-2013 Research”
Heart-Healthy Diet May be Healthy for Prostate Cancer
Brisdelle Okayed as First Nonhormonal Treatment for Hot Flashes
Expanding Active Surveillance Criteria
5-alpha Reductase Inhibitors for LUTS and Prevention of Prostate Cancer
Doctor Chodak’s Bottom Line
